Ovarian cancer stem cells and inflammation

References

• Jemal A, Center MM, Ward E, Thun MJ. Cancer occurrence. Methods Mol Biol 2009; 471:3 - 29
   PubMedGoogle Scholar
• Schwartz PE. Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat Res 2002; 107:99 - 118
   PubMedGoogle Scholar
• Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States 1970–2002. JAMA 2005; 294:1255 - 1259
   PubMed Web of Science ®Google Scholar
• Clarke MF, Fuller M. Stem cells and cancer: two faces of eve. Cell 2006; 124:1111 - 1115
   PubMed Web of Science ®Google Scholar
• Paguirigan A, Beebe DJ, Liu B, Alexander C. Mammary stem and progenitor cells: tumour precursors?. Eur J Cancer 2006; 42:1225 - 1236
   PubMed Web of Science ®Google Scholar
• Sell S. Stem cell origin of cancer and differentiation therapy. Crit Rev Oncol Hematol 2004; 51:1 - 28
   PubMed Web of Science ®Google Scholar
• Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006; 66:9339 - 9344
   PubMedGoogle Scholar
• Huang EH, Heidt DG, Li CW, Simeone DM. Cancer stem cells: a new paradigm for understanding tumor progression and therapeutic resistance. Surgery 2007; 141:415 - 419
   PubMed Web of Science ®Google Scholar
• Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer and cancer stem cells. Nature 2001; 414:105 - 111
   PubMed Web of Science ®Google Scholar
• Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009; 8:158 - 166
   PubMed Web of Science ®Google Scholar
• Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8:755 - 768
   PubMed Web of Science ®Google Scholar
• Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod Biol Endocrinol 2003; 1:66
   PubMedGoogle Scholar
• Li J, Sasaki H, Sheng YL, Schneiderman D, Xiao CW, Kotsuji F, et al. Apoptosis and chemoresistance in human ovarian cancer: is Xiap a determinant?. Biol Signals Recept 2000; 9:122 - 130
   PubMedGoogle Scholar
• Silasi DA, Alvero AB, Illuzzi J, Kelly M, Chen R, Fu HH, et al. MyD88 predicts chemoresistance to paclitaxel in epithelial ovarian cancer. Yale J Biol Med 2006; 79:153 - 163
   PubMedGoogle Scholar
• Chen R, Alvero AB, Silasi DA, Kelly MG, Fest S, Visintin I, et al. Regulation of IKKbeta by miR-199a affects NFkappaB activity in ovarian cancer cells. Oncogene 2008; 27:4712 - 4723
   PubMed Web of Science ®Google Scholar
• Bapat SA, Mali AM, Koppikar CB, Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer Res 2005; 65:3025 - 3029
   PubMed Web of Science ®Google Scholar
• Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68:4311 - 4320
   PubMed Web of Science ®Google Scholar
• Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS ONE 2010; 5:10277
   PubMed Web of Science ®Google Scholar
• Yu CC, Chiou GY, Lee YY, Chang YL, Huang PI, Cheng YW, et al. Medulloblastoma-derived tumor stem-like cells acquired resistance to TRAIL-induced apoptosis and radiosensitivity. Childs Nerv Syst 2010; 26:897 - 904
   PubMed Web of Science ®Google Scholar
• Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD, et al. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One 2010; 5:14062
   PubMed Web of Science ®Google Scholar
• Zhuge Y, Liu ZJ, Velazquez JC. Adult stem cell differentiation and trafficking and their implications in disease. Adv Exp Med Biol 2010; 695:169 - 183
   PubMed Web of Science ®Google Scholar
• Mazzone A, Epistolato MC, De Caterina R, Storti S, Vittorini S, Sbrana S, et al. Neoangiogenesis, T-lymphocyte infiltration and heat shock protein-60 are biological hallmarks of an immunomediated inflammatory process in end-stage calcified aortic valve stenosis. J Am Coll Cardiol 2004; 43:1670
   PubMed Web of Science ®Google Scholar
• Mazzucato M, Cozzi MR, Pradella P, Perissinotto D, Malmstrom A, Morgelin M, et al. Vascular PG-M/versican variants promote platelet adhesion at low shear rates and cooperate with collagens to induce aggregation. FASEB J 2002; 16:1903 - 1916
   PubMed Web of Science ®Google Scholar
• Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007; 13:543 - 551
   PubMed Web of Science ®Google Scholar
• Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 1998; 95:588 - 593
   PubMed Web of Science ®Google Scholar
• McDermott EP, O'Neill LA. Ras participates in the activation of p38 MAPK by interleukin-1 by associating with IRAK, IRAK2, TRAF6 and TAK-1. J Biol Chem 2002; 277:7808 - 7815
   PubMed Web of Science ®Google Scholar
• Ropert C, Closel M, Chaves AC, Gazzinelli RT. Inhibition of a p38/stress-activated protein kinase-2-dependent phosphatase restores function of IL-1 receptor-associate kinase-1 and reverses Toll-like receptor 2- and 4-dependent tolerance of macrophages. J Immunol 2003; 171:1456 - 1465
   PubMed Web of Science ®Google Scholar
• Dunne A, O'Neill LA. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci STKE 2003; 2003:3
   Google Scholar
• Shoham S, Huang C, Chen JM, Golenbock DT, Levitz SM. Toll-like receptor 4 mediates intracellular signaling without TNFalpha release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol 2001; 166:4620 - 4626
   PubMed Web of Science ®Google Scholar
• Abrahams VM, Bole-Aldo P, Kim YM, Straszewski-Chavez SL, Chaiworapongsa T, Romero R, et al. Divergent trophoblast responses to bacterial products mediated by TLRs. J Immunol 2004; 173:4286 - 4296
   PubMed Web of Science ®Google Scholar
• Abrahams VM, Mor G. Toll-like receptors and their role in the trophoblast. Placenta 2005; 26:540 - 547
   PubMed Web of Science ®Google Scholar
• Sirard JC, Bayardo M, Didierlaurent A. Pathogen-specific TLR signaling in mucosa: mutual contribution of microbial TLR agonists and virulence factors. Eur J Immunol 2006; 36:260 - 263
   PubMed Web of Science ®Google Scholar
• Shaykhiev R, Behr J, Bals R. Microbial patterns signaling via Toll-like receptors 2 and 5 contribute to epithelial repair, growth and survival. PLoS One 2008; 3:1393
   Web of Science ®Google Scholar
• Kim KH, Xie Y, Tytler EM, Woessner R, Mor G, Alvero AB. KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells. J Transl Med 2009; 7:63
   PubMed Web of Science ®Google Scholar
• Lee SH, Hong B, Sharabi A, Huang XF, Chen SY. Embryonic stem cells and mammary luminal progenitors directly sense and respond to microbial products. Stem Cells 2009; 27:1604 - 1615
   PubMed Web of Science ®Google Scholar
• Chen R, Alvero AB, Silasi DA, Mor G. Inflammation, cancer and chemoresistance: taking advantage of the toll-like receptor signaling pathway. Am J Reprod Immunol 2007; 57:93 - 107
   PubMed Web of Science ®Google Scholar
• Karin M. Nuclear factor kappaB in cancer development and progression. Nature 2006; 441:431 - 436
   PubMed Web of Science ®Google Scholar
• Luo JL, Kamata H, Karin M. The anti-death machinery in IKK/NFkappaB signaling. J Clin Immunol 2005; 25:541 - 550
   PubMed Web of Science ®Google Scholar
• Kelly MG, Alvero AB, Chen R, Silasi DA, Abrahams VM, Chan S, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res 2006; 66:3859 - 3868
   PubMed Web of Science ®Google Scholar
• Chen R, Alvero AB, Silasi DA, Steffensen KD, Mor G. Cancers take their Toll—the function and regulation of Toll-like receptors in cancer cells. Oncogene 2008; 27:225 - 233
   PubMed Web of Science ®Google Scholar
• Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, Glackin C, et al. TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 2010; 29:3545 - 3553
   PubMed Web of Science ®Google Scholar
• Bialek P, Kern B, Yang X, Schrock M, Sosic D, Hong N, et al. A twist code determines the onset of osteoblast differentiation. Dev Cell 2004; 6:423 - 435
   PubMed Web of Science ®Google Scholar
• Cheng GZ, Zhang W, Wang LH. Regulation of cancer cell survival, migration and invasion by Twist: AKT2 comes to interplay. Cancer Res 2008; 68:957 - 960
   PubMed Web of Science ®Google Scholar
• Cheng GZ, Zhang WZ, Sun M, Wang Q, Coppola D, Mansour M, et al. Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem 2008; 283:14665 - 14673
   PubMed Web of Science ®Google Scholar
• Isenmann S, Arthur A, Zannettino AC, Turner JL, Shi S, Glackin CA, et al. TWIST family of basic Helix-Loop-Helix Transcription Factors Mediate Human Mesenchymal Stromal/Stem Cell Growth and Commitment. Stem Cells 2009; 27:2457 - 2468
   PubMed Web of Science ®Google Scholar
• Barnes RM, Firulli AB. A twist of insight—the role of Twist-family bHLH factors in development. Int J Dev Biol 2009; 53:909 - 924
   PubMed Web of Science ®Google Scholar
• Lee YB, Bantounas I, Lee DY, Phylactou L, Caldwell MA, Uney JB. Twist-1 regulates the miR-199a/214 cluster during development. Nucleic Acids Res 2009; 37:123 - 128
   PubMed Web of Science ®Google Scholar
• Baylies MK, Bate M. twist: a myogenic switch in Drosophila. Science 1996; 272:1481 - 1484
   PubMedGoogle Scholar
• Watanabe O, Imamura H, Shimizu T, Kinoshita J, Okabe T, Hirano A, et al. Expression of twist and wnt in human breast cancer. Anticancer Res 2004; 24:3851 - 3856
   PubMed Web of Science ®Google Scholar
• Puisieux A, Valsesia-Wittmann S, Ansieau S. A twist for survival and cancer progression. Br J Cancer 2006; 94:13 - 17
   PubMed Web of Science ®Google Scholar
• Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, et al. Upregulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 2005; 65:5153 - 5162
   PubMed Web of Science ®Google Scholar